Research ArticleTheranostics
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn and Frederik L. Giesel
Journal of Nuclear Medicine June 2019, 60 (6) 801-805; DOI: https://doi.org/10.2967/jnumed.119.227967
Clemens Kratochwil
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Paul Flechsig
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
Thomas Lindner
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Labidi Abderrahim
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Annette Altmann
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
3Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
Walter Mier
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Sebastian Adeberg
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Heidelberg Institute for Radiation Oncology, Heidelberg, Germany
Hendrik Rathke
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Manuel Röhrich
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Hauke Winter
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
6Department of Surgery, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany
Peter K. Plinkert
7Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany
Frederik Marme
8Department Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany
9Department Obstetrics and Gynecology, University Hospital Mannheim, Mannheim, Germany
Matthias Lang
10Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
Hans-Ulrich Kauczor
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
11Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
Dirk Jäger
12Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Germany
13Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany; and
Jürgen Debus
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Heidelberg Institute for Radiation Oncology, Heidelberg, Germany
14Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
Uwe Haberkorn
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
3Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
Frederik L. Giesel
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 6
June 1, 2019
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel
Journal of Nuclear Medicine Jun 2019, 60 (6) 801-805; DOI: 10.2967/jnumed.119.227967
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel
Journal of Nuclear Medicine Jun 2019, 60 (6) 801-805; DOI: 10.2967/jnumed.119.227967
Jump to section
Related Articles
Cited By...
- 68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma
- 68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression
- Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial
- Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
- The Current and Future Roles of Precision Oncology in Advanced Breast Cancer
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Metabolic and molecular imaging in inflammatory arthritis
- Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
- Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer
- Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT
- Imaging Agents for PET of Inflammatory Bowel Disease: A Review
- Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
- PET imaging of fibroblast activation protein alpha (FAP) detects incipient cardiotoxicity due to anthracycline chemotherapy
- Performance of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with 18F-FDG PET/CT
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study
- Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
- Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- 18F-FDG PET/CT in the Management of Osteosarcoma
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- 18F-FDG PET/CT in the Management of Osteosarcoma
- Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
- Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
- Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
- PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study
- Static and Dynamic 68Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas
- Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy
- FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment
- Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions
- Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model
- Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
- Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept
- Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
- Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome
- Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study
- Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
- The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis
- Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
- A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates
- Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
- A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
- Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT
- 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
- 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT
- Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study
- Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis
- The Annual Journal Impact Factor Saga
- CD40 Agonist Targeted to Fibroblast Activation Protein {alpha} Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors
- Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
- (Oligo)metastasis as a Spectrum of Disease
- An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
- FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
- Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX
- The Latest Developments in Imaging of Fibroblast Activation Protein
- Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
- FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
- High-resolution positron emission microscopy of patient-derived tumor organoids
- Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- A Conversation Between Uwe Haberkorn and Johannes Czernin